635701-88-1

Basic information

• Product Name: 4-[5-(4-ISOBUTYL-PHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZALDEHYDE
• Synonyms: 4-[5-(4-ISOBUTYL-PHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZALDEHYDE;4-[5-[4-(2-Methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]benzaldehyde;Benzaldehyde, 4-[5-[4-(2-Methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]-
• CAS NO: 635701-88-1
• Molecular Formula: C₁₉H₁₈N₂O₂
• Molecular Weight: 306.36
• Mol File: 635701-88-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 469.4 °C at 760 mmHg
• Flash Point: 237.7 °C
• Appearance: /
• Density: 1.146
• CAS DataBase Reference: 4-[5-(4-ISOBUTYL-PHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[5-(4-ISOBUTYL-PHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZALDEHYDE(635701-88-1)
• EPA Substance Registry System: 4-[5-(4-ISOBUTYL-PHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZALDEHYDE(635701-88-1)

Safety Data

• Hazardous Substances Data: 635701-88-1(Hazardous Substances Data)

Usage

General Description

4-[5-(4-isobutyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzaldehyde is a chemical compound consisting of a benzaldehyde group attached to a 1,2,4-oxadiazole ring, which in turn is linked to a 4-isobutyl-phenyl group. The compound has potential applications in medicinal chemistry, specifically as a building block for the synthesis of pharmaceuticals. Its structure suggests it may have biological activity and could potentially be used as a chemical probe in drug discovery research. Its unique structure gives it properties that could be of interest for further study and potential applications in various fields.

Upstream product

• 635702-24-8 4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl alcohol 
• 635702-23-7 (E)-N′-hydroxy-4-(hydroxymethyl)benzimidamide 
• 874-89-5 4-Cyanobenzyl alcohol 
• 79-37-8 oxalyl dichloride 
• 1233243-49-6 (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide 
• 635702-23-7 N-hydroxy-4-(hydroxymethyl)benzenecarboximidamide 

Downstream Products

• 635701-59-6 1-{4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl}-3-azetidine carboxylic acid 
• 635702-41-9 (+/-)-4-(5-(4-(2-methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl)-1-(1-hydroxyethyl)benzene 
• 891858-61-0 2-({4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)ethanol 

Relevant articles and documents

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF

Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocylcic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof; a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.

AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF

A compound represented by the general formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug of any of these; and a drug containing any of these. (I) (In the formula, all the symbols are as defined in the description.) The compound represented by the general formula (I) has the ability to combine with an S1P receptor (especially EDG-1, EDG-6, and/or EDG-8). It is useful for the prevention and/or treatment of rejection reactions to transplantation, graft versus host diseases, autoimmune diseases, allergic diseases, neurodegenerative diseases, etc.